Manipulating these intestinal immune cell populations and/or their secreted factors, such as via administration of all-trans-RA, might serve as a therapeutic avenue for obesity-associated metabolic dysfunction by enhancing IgA presence in the colon to curb the pathogenic consequences of a dysbiotic penetrant microbiota47–49. Here, CD79A is linked to obesity disorder.